LinkedIn Image

Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma

Meeting Overview

We are pleased to invite you to our satellite symposium, Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma, to be held on Thursday, 22 June 2017 in conjunction with the 22nd Congress of the European Hematology Association.

This satellite symposium has been designed to provide participants with an overview of currently approved therapies and new targets for patients with either transplant-eligible or transplant-ineligible relapsed/refractory multiple myeloma (R/R MM). Common treatment-emergent adverse events associated with different classes of therapeutic agents in R/R MM will also be covered.

Agenda

08.00 Welcome, introduction, and pop quiz
Meletios Dimopoulos, MD
08.05 Looking back to shore: How did we get to R/R MM?
Philippe Moreau, MD
08.25 Q & A
08.30 Pop quiz
08.35 Wind in our sails: Next-generation therapeutic options in R/R MM
Meletios Dimopoulos, MD
08.55 Q & A
09.00 Pop quiz
09.05 What’s on the near horizon? New targets in R/R MM
Sagar Lonial, MD
09.25 Q & A
09.30 Pop quiz
09.35 Avoiding treacherous waters: Balancing efficacy with adversity
Enrique Ocio, MD, PhD
09.55 Q & A
10.00 Conclusion and key points
Meletios Dimopoulos, MD

Faculty

CHAIR
  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
FACULTY
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Philippe Moreau, MDUniversity of Nantes
    Nantes, France
  • Enrique Ocio, MD, PhDUniversity of Salamanca
    Salamanca, Spain

Target Audience

This educational activity is designed for hematologists, oncologists, patient advocates, and other healthcare providers involved and/or interested in the management of patients with multiple myeloma (MM).

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Distinguish initial therapeutic strategies for patients who are transplant-eligible versus patients who are transplant-ineligible in the newly diagnosed MM setting
  • Describe the pivotal trials that have led to recent approval of therapies in R/R MM
  • Summarize new targets for therapy in R/R MM currently in late phase clinical trials
  • Identify the common treatment-emergent adverse events associated with different classes of therapeutic agents used in R/R MM

Continuing Education

Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma is designated for a maximum of 2 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Support

This educational activity is supported by Celgene, Karyopharm Therapeutics, and PharmaMar.

Register Now

Date and Location

Thursday, 22 June 2017
08.00 – 10.00

Hall D
IFEMA – Feria de Madrid
Av. Partenón, 5
Madrid, Spain

Printed Materials

Printed Materials

Provider

This activity is provided by prIME Oncology.

Good CME Practice

gCMEp-FINAL-logo-1

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.